<section id ="1036585-1309736" class="mfp-hide modal-dialog modal-content overlay-def"><header class="modal-header"><h2 class="modal-title">2017, c. 6, s. 56</h2></header><div class="modal-body"><p class="MarginalNote"><span class="wb-invisible">Marginal note:</span><span class="HistoricalNote">1993, c. 2, s. 7</span></p><p class="Section amending" id="1036585"><strong><a class="sectionLabel" id="s-56"><span class="sectionLabel">56</span></a></strong> Subsections 100(2) and (3) of the Act are replaced by the following:</p><section><div class="AmendedText"><ul class="Section ProvisionList" id=""><li><p class="MarginalNote"><span class="wb-invisible">Marginal note:</span>Contents</p><p class="Subsection"><span class="lawlabel">(2)</span> The report shall contain</p><ul class="ProvisionList"><li><p class="Paragraph"><span class="lawlabel">(a)</span> a summary of pricing trends in the pharmaceutical industry; and</p></li><li><p class="Paragraph"><span class="lawlabel">(b)</span> the name of each rights holder and former rights holder in respect of whom an order was made under subsection 81(1) or 82(2) or section 83 during the year and a statement as to the status of the matter in respect of which the order was made.</p></li></ul></li><li><p class="MarginalNote"><span class="wb-invisible">Marginal note:</span>Report summary</p><p class="Subsection"><span class="lawlabel">(3)</span> The summary referred to in paragraph (2)(a) may be based on information and documents provided to the Board by any rights holder or former rights holder under section 80, 81 or 82 or in any proceeding under section 83, but shall not be set out in a manner that would make it possible to identify that rights holder or former rights holder.</p></li></ul></div></section></div></section>